Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: Results of a randomized trial

Leukemia and Lymphoma

Volumn 55, Issue 7, 2014, Pages 1489-1497

  Dimopoulos, Meletios A ^a   Palumbo, Antonio ^b   Hajek, Roman ^c   Kropff, Martin ^d   Petrucci, Maria Teresa ^e   Lewis, Philip ^f   Millar, Stefanie ^g   Zhang, Jingshan ^h   Mei, Jay ^h   Delforge, Michel ⁱ  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f Celgene GmbH   (Germany)

^g ICON CLINICAL RESEARCH   (United States)

^h CELGENE CORPORATION   (United States)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Health related quality of life (HRQoL); Lenalidomide; Minimal important difference (MID); Multiple myeloma; QLQ C30; QLQ MY20

Indexed keywords

LENALIDOMIDE; MELPHALAN; PLACEBO; PREDNISONE; ANTINEOPLASTIC AGENT; THALIDOMIDE;

AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; FUNDING; HUMAN; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; AGE; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; INDUCTION CHEMOTHERAPY; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MALE; MELPHALAN; MULTIPLE MYELOMA; NEOPLASM STAGING; PREDNISONE; QUALITY OF LIFE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84899145703     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.847933     Document Type: Article

References (13)

1. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomidetreatment for newly diagnosed multiple myeloma. NEngl J Med2012 ; 366 : 1759-1769.
2. Palumbo A, Hajek R, Kropff M, et al. Continuous lenalidomidetreatment for transplant-ineligible newly diagnosed multiplemyeloma: update on patients aged 65-75 years enrolled in MM-015.Haematologica 2012; 97(Suppl. 1): Abstract 0834.
3. Jaeschke R, Singer J, Guyatt GH. Measurement of health status.Ascertaining the minimal clinically important diff erence. Control ClinTrials 1989 ; 10 : 407-415.
4. Dimopoulos M, Delforge M, Hajek R, et al. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenanceimproves health-related quality of life in newly diagnosed multiplemyeloma patients aged 65 years or older: results of a randomized phaseIII trial. Haematologica 2013 ; 98 : 784-788.
5. Calvert M, Blazeby J, Altman DG, et al. ; CONSORT PRO Group.Reporting of patient-reported outcomes in randomized trials: theCONSORT PRO extension. JAMA 2013; 309: 814-822.
6. Aaronson NK, Ahmedzai S, Bergman B, et al. The EuropeanOrganization for Research and Treatment of Cancer QLQ-C30: aquality-of-life instrument for use in international clinical trials inoncology. JNatl Cancer Inst 1993 ; 85 : 365-376.
7. Cocks K, Cohen D, Wisloff F, et al. ; E ORTC Quality of Life Group.An international fi eld study of the reliability and validity of a diseasespecific questionnaire module (the QLQ-MY20) in assessing qualityof life of patients with multiple myeloma. Eur J Cancer 2007 ; 43 :1670-1678.
8. EORTC Quality of Life. FAQs. Available from: h ttp://groups.eortc.be/qol/ faq
9. EORTC Quality of Life. Manuals. Available from: h ttp://groups.eortc.be/ qol/manuals
10. Wyrwich KW, Nienaber NA, Tierney WM, et al. Linkingclinical relevance and statistical signifi cance in evaluating intraindividualchanges in health-related quality of life. Med Care 1999 ;37 : 469-478.
11. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidencesupporting an SEM-based criterion for identifying meaningful intraindividualchanges in health-related quality of life. J Clin Epidemiol1999 ; 52 : 861-873.
12. Stratford PW, Binkley JM, Riddle DL. Health status measures:strategies and analytic methods for assessing change scores. Phys Ther1996 ; 76 : 1109-1123.
13. Delforge M, Dhawan R, Robinson D Jr, et al. Health-relatedquality of life in elderly, newly diagnosed multiple myeloma patientstreated with VMP vs. MP: results from the VISTA trial. Eur J Haematol2012 ; 89 : 16-27.